Tissue Dynamics and Galmed Launch 20,000-Organoid Platform for Aramchol Cardiac Fibrosis Research
Tissue Dynamics and Galmed Pharmaceuticals will develop a vascularized, sensor-embedded human cardiac organoid platform to model chronic fibrosis and accelerate Aramchol-based therapeutic research. The DynamiX® system will enable high-throughput monitoring of over 20,000 organoids to assess SCD1-driven lipid metabolism, fibrosis, and tissue repair in post-MI and HFpEF settings.
1. Collaboration Overview
Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. have entered a collaboration to create a human-centric chronic cardiac fibrosis platform. The partnership aims to leverage Tissue Dynamics' DynamiX® organoid technology with Galmed's Aramchol and SCD1 expertise to model disease mechanisms.
2. Platform Technology
The DynamiX® system generates vascularized, multichambered cardiac organoids embedded with real-time metabolic sensors and automation capable of testing over 20,000 organoids in parallel. It captures longitudinal data on metabolism, fibrosis, electrical conduction, and inflammatory signaling.
3. Therapeutic Focus and Objectives
The platform will initially focus on chronic remodeling after myocardial infarction and HFpEF, linking lipid metabolism, SCD1 activity, and fibrotic pathways. This approach addresses a key gap in human-relevant models for evaluating therapies that reverse fibrosis.
4. Implications for Aramchol Development
By integrating AI-driven analysis of structural, functional, and molecular endpoints, the model is designed to accelerate preclinical screening of Aramchol-based candidates, combinations, and dosing strategies. Galmed expects this platform to inform development of interventions that correct metabolic dysfunction and enhance tissue repair.